Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Liabilities and Shareholders Equity: 2010-2024

Historic Liabilities and Shareholders Equity for Anika Therapeutics (ANIK) over the last 15 years, with Dec 2024 value amounting to $202.7 million.

  • Anika Therapeutics' Liabilities and Shareholders Equity fell 18.14% to $189.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $770.5 million, marking a year-over-year decrease of 25.08%. This contributed to the annual value of $202.7 million for FY2024, which is 25.09% down from last year.
  • Latest data reveals that Anika Therapeutics reported Liabilities and Shareholders Equity of $202.7 million as of FY2024, which was down 25.09% from $270.6 million recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' Liabilities and Shareholders Equity registered a high of $365.6 million during FY2020, and its lowest value of $202.7 million during FY2024.
  • For the 3-year period, Anika Therapeutics' Liabilities and Shareholders Equity averaged around $274.2 million, with its median value being $270.6 million (2023).
  • In the last 5 years, Anika Therapeutics' Liabilities and Shareholders Equity rose by 10.55% in 2020 and then fell by 25.09% in 2024.
  • Yearly analysis of 5 years shows Anika Therapeutics' Liabilities and Shareholders Equity stood at $365.6 million in 2020, then dropped by 4.94% to $347.5 million in 2021, then grew by 0.46% to $349.1 million in 2022, then decreased by 22.48% to $270.6 million in 2023, then declined by 25.09% to $202.7 million in 2024.